The TOE alone group had no effect, while the TOE + CIS group showed partial recovery: decreased sensory latencies (−20–30%,p < 0.05) and improved rotarod scores (+25%,p < 0.001), consistent with in silico NF-κB1 inhibition. The gene discussed is NFKB1; the disease is in situ carcinoma.